SCHEMBL26099191

SCHEMBL26099191

COc1c(N)cccc1C1CCC(=O)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.38
ALOX5AP P20292 4/20 0.38
FEN1 P39748 4/20 0.38
POLL Q9UGP5 1/20 0.37
GRM7 Q14831 2/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
PDE10A Q9Y233 1/20 0.36
PDK2 Q15119 1/20 0.36
PDK4 Q16654 1/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
ESR2 Q92731 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30392122 1.00 HTR2C (0.38) HTR2CALOX5APFEN1POLLGRM7
SCHEMBL28092534 0.88 HTR2C (0.43) HTR2CALOX5APFEN1PDK2PDK4
SCHEMBL27416896 0.83 FEN1 (0.47) HTR2CALOX5APFEN1MEN1KMT2A
SCHEMBL27812820 0.82 HTR2C (0.58) HTR2C
SCHEMBL26100704 0.82 ALOX5AP (0.35) HTR2CALOX5APFEN1GRM7CA1
SCHEMBL521037 0.79 HTR1D (0.43) HTR2CALOX5APFEN1MEN1KMT2A
SCHEMBL7065427 0.76 PARP1 (0.39) HTR2CALOX5APFEN1MEN1KMT2A
SCHEMBL26100868 0.76 CA1 (0.37) POLLCA1CA2KDM4EMEN1
SCHEMBL30392792 0.75 PDE10A (0.39) HTR2CALOX5APFEN1PDE10APOLB
SCHEMBL26100067 0.75 PDE10A (0.39) HTR2CALOX5APFEN1PDE10APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-02-13 US disclosed
EP-4423086-A1 TYK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-09-04 EP disclosed
WO-2023076161-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-05-04 WO disclosed
WO-2023076161-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, DYRK2, DYRK1A HTR2C 2094/4885ALOX5AP 2993/4885FEN1 1905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.